ALT · Altimmune, Inc.

NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD

Altimmune Inc (ALT)

NASDAQ NMS - GLOBAL MARKET Biotechnology
Move probability → Options chain →
$2.23 -0.06 (-2.62%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE $2.23
$2.19 $2.34
52-WEEK RANGE $2.23
$2.17 $6.44

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$433.8M
P/E (TTM1)—
EPS2 (TTM)$-0.78
Div Yield—
Beta30.05
Volume230,601
Open2.29
Prev Close2.29
Bid / Ask1.90 / 2.54
Next Earnings 2026-11-10 (before market open)

Analyst Recommendations

Strong buy 4 Buy 9 Hold 2 Sell 0 Strong sell 0

Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
ALT -38.23%
vs S&P 500 -51.60%
1-YEAR RETURN
ALT -44.80%
vs S&P 500 -59.97%
6-MONTH RETURN
ALT -36.29%
3-MONTH RETURN
ALT -20.64%

Valuation Measures & Ratios

Enterprise Value4$416.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)10840.80
Price / Book71.25
EV4 / Revenue10151.39
EV4 / EBITDA—
Profit Margin-214860.98%
Operating Margin-230460.98%
Return on Equity (ROE8)-31.41%
Return on Assets (ROA9)-26.96%
Avg Volume (3M)4,348,300
Quarterly history (5 periods)
Measure Jun '26Mar '26Sep '25Jun '25Mar '25
Market cap $577.3M $384.8M $341.3M $317.0M $375.7M
P/E -6.67 -4.62 -4.08 -3.55 -4.11
Price/Sales — — 17067.33 15850.79 18784.47
Price/Book 1.22 1.36 1.84 1.96 2.64
EV/Revenue — — 14727.78 7412.14 16329.27
ROE -18.25% -29.33% -45.03% -55.28% -64.33%
ROA -16.42% -24.82% -38.26% -46.86% -58.15%

Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).

Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short46,079,911
Change from Prior Settlement-10.96%
% of Float—
Days to Cover (Short Ratio)10.54

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Not investment advice — read several signals together.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

History limited by data provider; markers are heuristics, not signals.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

  • Latest SEC filing is Form 4, filed 2026-10-05; review it for current changes and risks. SEC EDGAR ↗

Potential concerns

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

Financials

Income statement

Line item Jun '26Mar '26Sep '25Jun '25Mar '25Sep '24Jun '24Mar '24
Revenue — — $5.0K $5.0K $5.0K $5.0K $5.0K $5.0K
Operating income -$26.2M -$24.2M -$20.9M -$22.9M -$21.8M -$24.8M -$26.7M -$26.8M
Net income -$22.8M -$22.6M -$19.0M -$22.1M -$19.6M -$22.8M -$24.6M -$24.4M
EPS (diluted) $-0.12 $-0.18 $-0.21 $-0.27 $-0.26 $-0.32 $-0.35 $-0.34
EPS (basic) $-0.12 $-0.18 $-0.21 $-0.27 $-0.26 $-0.32 $-0.35 $-0.34
Operating margin — — -$417.2K -$458.4K -$436.3K -$495.3K -$534.9K -$535.9K

Balance sheet

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Total assets $527.2M $335.6M $279.9M $218.4M $190.3M $157.3M $139.3M $147.9M
Total liabilities $53.0M $51.6M $55.0M $32.8M $29.0M $15.1M $15.8M $14.5M
Stockholders' equity $474.2M $284.0M $224.9M $185.6M $161.4M $142.2M $123.5M $133.4M
Total current assets $334.8M $334.7M $278.2M $216.6M $188.4M $155.3M $137.3M $145.8M
Total current liabilities $12.5M $11.3M $15.0M $12.6M $9.2M $9.8M $10.5M $8.6M
Cash & equivalents $63.0M $97.6M $43.8M $61.2M $183.1M $49.1M $36.9M $31.5M

Cash flow

Line item Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24
Operating cash flow -$24.2M -$20.9M -$19.4M -$11.9M -$19.4M -$16.8M -$18.3M -$27.1M
Investing cash flow -$221.4M -$3.7M -$79.2M -$149.3M $101.1M -$5.1M $13.6M $1.2M
Financing cash flow $211.1M $78.5M $81.1M $39.3M $52.2M $34.1M $10.1M $266.0K
Free cash flow -$24.3M -$21.0M -$19.4M -$11.9M -$19.4M — — —
Capital expenditures $32.0K $21.0K $1.0K $0 $10.0K — — —
Depreciation & amortization — — — — — — — —

Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.

Institutional holders

SEC Form 13F filers holding ALT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

Institutional ownership is not available for this symbol right now.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

Insider activity is not available for this symbol right now.

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR submissions · updated 2026-10-22 05:54 UTC

FiledFormReport periodOfficial filing
2026-10-0542026-10-01 View on SEC.gov →
2026-10-0542026-10-01 View on SEC.gov →
2026-10-0242026-10-01 View on SEC.gov →
2026-09-298-K2026-09-24 View on SEC.gov →
2026-09-1742026-09-16 View on SEC.gov →
2026-08-1342026-08-13 View on SEC.gov →
2026-08-1210-Q2026-06-30 View on SEC.gov →
2026-08-128-K2026-08-12 View on SEC.gov →
2026-08-0342026-07-31 View on SEC.gov →
2026-08-0342026-07-31 View on SEC.gov →
2026-07-288-K2026-07-28 View on SEC.gov →
2026-06-168-K2026-06-16 View on SEC.gov →

Headlines about ALT (Altimmune, Inc.). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist